Stock Alert: ADMA Biologics Jumps 37%

Shares of ADMA Biologics, Inc. (ADMA) are currently gaining over 37% on Thursday morning despite no stock related news to drive the shares.

U.S. stocks traded sharply lower on Thursday morning, as investors are pessimistic about economic rebound due to spike in COVID-19 cases. Meanwhile, shares of pharma companies are performing better lately driven by the positive reports of COVID-19 vaccine.

ADMA is currently trading at $3.8927, up $1.0527 or 37.07%, on the Nasdaq. The stock has traded between $1.45 and $4.65 in the year-to-date period.

ADMA Biologics will release its second quarter financial results on August 5.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT